Indication: Ovarian Cancer
A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Sub-indication: Epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Line of Therapy: Front-line neoadjuvant and post surgical therapy.
Principal Investigator: Mary Gordinier, M.D.Norton Cancer Institute
Sponsor: NRG Oncology
Email for more information: GYN-NCIResearch@nortonhealthcare.org